PLL Therapeutics appoints Dr. Souad Kechairi as chief medical officer
Dr. Kechairi strengthens clinical team to advance PLL Therapeutics’ autoimmune and neurodegenerative diseases pipeline and enter phase 1 clinical trials with lead candidate for Amyotrophic Lateral Sclerosis (ALS)...